Related trials
Buse, 2011 - exenatide vs placebo add on insulin
Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)
DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin
DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine
Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET
DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone
Goodman, 2009 - vildagliptin vs placebo (add on to metformin)
HOME, 2009 - metformin vs placebo
LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET
Nauck (Sulf vs pbo), 2009 - vs placebo
9607, 2009 - exenatide vs placebo add on MET+/-SU
Li, 2009 - nateglinide vs repaglinide
LEAD-2 (vs MET), 2009 - liraglutide vs metformin
Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)
LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride
Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )
COSMIC, 2009 - vs
LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET
DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)
RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs
Nauck, 2009 - alogliptin vs placebo (add on to metformin)
Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog
Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide
Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)
Moretto, 2008 - exenatide vs placebo
See also:
All test diabète clinical trials
All diabetes clinical trials
All type 2 diabetes - sanofi clinical trials
All clinical trials of insulin secretagogues peptides (incretins)
All clinical trials of liraglutide
|
|
Treatments
Studied treatment |
Liraglutide 1.8 mg daily
|
Control treatment |
Glargine on-top of sulphonylureas+metformin
|
Concomittant treatment |
sulphonylureas+/-metformin |
Patients
Baseline characteristics |
Age (year) |
57 |
Duration of diabetes (year) |
9.4 y |
HbA1c (%) |
8.2 |
BMI |
30.5 |
Add-on to |
SU+/-Met |
|
Method and design
Randomized effectives |
230 / 232 (studied vs. control) |
Blinding |
not reported |
Follow-up duration |
26 weeks |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
nausea
32 / 230
3 / 232
classic
10,76 [3,34;34,64]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
nausea
|
32 / 230 (13,9%) |
3 / 232 (1,3%) |
10,76 |
[3,34;34,64] |
|
0 |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
nausea |
13,91% |
1,29% |
12,6%
|
Meta-analysis of all similar trials:
antidiabetic drugs in test diabète for type 2 daibetes (NIDD)
insulin secretagogues peptides (incretins) in diabetes for all type of patients
insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients
Reference(s)
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R, , .
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial..
Diabetologia 2009;52:2046-55.
- 10.1007/s00125-009-1472-y
Pubmed
|
Hubmed
| Fulltext
-
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R.
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial..
Diabetologia 2009 Oct;52:2046-55
Pubmed
|
Hubmed
| Fulltext
-
Sullivan SD, Alfonso-Cristancho R, Conner C, Hammer M, Blonde L.
Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone..
Cardiovasc Diabetol 2009 Feb 26;8:12
Pubmed
|
Hubmed
| Fulltext
|